Bioactivation and reactivity research advances – 2022 year in review‡

With the 50th year mark since the launch of Drug Metabolism and Disposition journal, the field of drug metabolism and bioactivation has advanced exponentially in the past decades (Guengerich 2023).This has, in a major part, been due to the continued advances across the whole spectrum of applied technologies in hardware, software, machine learning (ML), and artificial intelligence (AI). LC-MS platforms continue to evolve to support key applications in the field, and automation is also improving the accuracy, precision, and throughput of these supporting assays. In addition, sample generation and processing is being aided by increased diversity and quality of reagents and bio-matrices so that what is being analyzed is more relevant and translatable. The application of in silico platforms (applied software, ML, and AI) is also making great strides, and in tandem with the more traditional approaches mentioned previously, is significantly advancing our understanding of bioactivation pathways and how these play a role in toxicity. All of this continues to allow the area of bioactivation to evolve in parallel with associated fields to help bring novel or improved medicines to patients with urgent or unmet needs.Shuai Wang and Cyrus Khojasteh, on behalf of the authors.

[1]  A. Mahipal,et al.  Pemigatinib in cholangiocarcinoma with a FGFR2 rearrangement or fusion , 2022, Expert review of anticancer therapy.

[2]  P. Loria,et al.  Discovery of Ervogastat (PF-06865571): A Potent and Selective Inhibitor of Diacylglycerol Acyltransferase 2 for the Treatment of Non-alcoholic Steatohepatitis. , 2022, Journal of medicinal chemistry.

[3]  K. Mitra.  Acyl Glucuronide and Coenzyme A Thioester Metabolites of Carboxylic Acid-Containing Drug Molecules: Layering Chemistry with Reactive Metabolism and Toxicology. , 2022, Chemical research in toxicology.

[4]  M. Shah.  Inhibition of CYP2C8 by Acyl Glucuronides of Gemfibrozil and Clopidogrel: Pharmacological Significance, Progress and Challenges , 2022, Biomolecules.

[5]  K. Parkes,et al.  Non-innocuous Consequences of Metabolic Oxidation of Alkyls on Arenes. , 2022, Journal of medicinal chemistry.

[6]  M. Redinbo,et al.  The in vitro metabolism and in vivo pharmacokinetics of the bacterial β-glucuronidase inhibitor UNC10201652 , 2022, Xenobiotica; the fate of foreign compounds in biological systems.

[7]  F. Guengerich.  Drug Metabolism: A Half-Century Plus of Progress, Continued Needs, and New Opportunities , 2022, Drug Metabolism and Disposition.

[8]  Lei Zhou,et al.  Metabolic Activation of the Acrylamide Michael Acceptor Warhead in Futibatinib to an Epoxide Intermediate Engenders Covalent Inactivation of CYP3A , 2022, Drug Metabolism and Disposition.

[9]  Wei Li,et al.  Metabolic Activation and Cytotoxicity of Propafenone Mediated by CYP2D6. , 2022, Chemical research in toxicology.

[10]  S. Shimma,et al.  Metabolite alteration analysis of acetaminophen-induced liver injury using a mass microscope , 2022, Analytical and Bioanalytical Chemistry.

[11]  Lei Zhou,et al.  Direct and Sequential Bioactivation of Pemigatinib to Reactive Iminium Ion Intermediates Culminates in Mechanism-Based Inactivation of Cytochrome P450 3A , 2022, Drug Metabolism and Disposition.

[12]  Xiangge Tian,et al.  Unique Oxidative Metabolism of Bufalin Generates Two Reactive Metabolites That Strongly Inactivate Human Cytochrome P450 3A. , 2022, Journal of medicinal chemistry.

[13]  T. Taniguchi,et al.  A cysteine trapping assay for risk assessment of reactive acyl CoA metabolites , 2022, Xenobiotica; the fate of foreign compounds in biological systems.

[14]  M. Yanagita,et al.  Unexpected cause of vemurafenib-induced nephrotoxicity: ferrochelatase. , 2021, Kidney international.

[15]  Xuben Yu,et al.  Hepatotoxicity-Related Adverse Effects of Proton Pump Inhibitors: A Cross-Sectional Study of Signal Mining and Analysis of the FDA Adverse Event Report System Database , 2021, Frontiers in Medicine.

[16]  M. Inglot,et al.  ACC inhibitor alone or co-administered with a DGAT2 inhibitor in patients with non-alcoholic fatty liver disease: two parallel, placebo-controlled, randomized phase 2a trials , 2021, Nature Medicine.

[17]  S. Baker,et al.  Kidney toxicity of the BRAF-kinase inhibitor vemurafenib is driven by off-target ferrochelatase inhibition. , 2021, Kidney international.

[18]  K. Rockich,et al.  Evaluation of drug-drug interactions of pemigatinib in healthy participants , 2021, European Journal of Clinical Pharmacology.

[19]  Noah R. Flynn,et al.  Bioactivation of Isoxazole-Containing Bromodomain and Extra-Terminal Domain (BET) Inhibitors , 2021, Metabolites.

[20]  R. Kreider,et al.  Creatine in Health and Disease , 2021, Nutrients.

[21]  David A. Price,et al.  Optimizing the Benefit/Risk of Acetyl-CoA Carboxylase (ACC) Inhibitors Through Liver Targeting. , 2020, Journal of medicinal chemistry.

[22]  F. Meric-Bernstam,et al.  Phase I, first-in-human study of futibatinib, a highly selective, irreversible FGFR1–4 inhibitor in patients with advanced solid tumors , 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

[23]  A. Kalgutkar.  Designing Around Structural Alerts in Drug Discovery. , 2020, Journal of medicinal chemistry.

[24]  S. Conway,et al.  Chemische Epigenetik: der Einfluss chemischer und chemo‐biologischer Techniken auf die Zielstruktur‐Validierung von Bromodomänen , 2019, Angewandte Chemie.

[25]  B. Goodwin,et al.  Targeting diacylglycerol acyltransferase 2 for the treatment of nonalcoholic steatohepatitis , 2019, Science Translational Medicine.

[26]  E. Chatelut,et al.  Identifying the reactive metabolites of tyrosine kinase inhibitors in a comprehensive approach: Implications for drug‐drug interactions and hepatotoxicity , 2019, Medicinal research reviews.

[27]  Y. Toyoda,et al.  Quantitative Evaluation of Reactivity and Toxicity of Acyl Glucuronides by [35S]Cysteine Trapping. , 2019, Chemical research in toxicology.

[28]  R. Sims,et al.  Bromodomains: a new target class for drug development , 2019, Nature Reviews Drug Discovery.

[29]  Kuei Ting Kuo,et al.  New therapeutic aspects of steroidal cardiac glycosides: the anticancer properties of Huachansu and its main active constituent Bufalin , 2019, Cancer Cell International.

[30]  U. Argikar,et al.  New Perspectives on Acyl Glucuronide Risk Assessment in Drug Discovery: Investigation of In vitro Stability, In situ Reactivity, and Bioactivation , 2018, Drug metabolism letters.

[31]  L. Kuepfer,et al.  Spatio-temporal visualization of the distribution of acetaminophen as well as its metabolites and adducts in mouse livers by MALDI MSI , 2018, Archives of Toxicology.

[32]  P. Biggin,et al.  BET bromodomain ligands: Probing the WPF shelf to improve BRD4 bromodomain affinity and metabolic stability. , 2018, Bioorganic & medicinal chemistry.

[33]  Guilherme H. Oliveira,et al.  Cardiotoxicity of Novel Targeted Chemotherapeutic Agents , 2018, Current Treatment Options in Cardiovascular Medicine.

[34]  A. Minidis,et al.  Systematic Approach to Organizing Structural Alerts for Reactive Metabolite Formation from Potential Drugs. , 2018, Chemical research in toxicology.

[35]  U. Argikar.  Saccharolactone: The History, the Myth, and the Practice. , 2017, Current drug metabolism.

[36]  I. Glezerman,et al.  Kidney Toxicities Associated With Novel Cancer Therapies. , 2017, Advances in chronic kidney disease.

[37]  J. Uetrecht,et al.  How Reactive Metabolites Induce an Immune Response That Sometimes Leads to an Idiosyncratic Drug Reaction. , 2017, Chemical research in toxicology.

[38]  J. Bolton,et al.  Formation and Biological Targets of Quinones: Cytotoxic versus Cytoprotective Effects , 2016, Chemical research in toxicology.

[39]  T. Heightman,et al.  Isoxazole‐Derived Amino Acids are Bromodomain‐Binding Acetyl‐Lysine Mimics: Incorporation into Histone H4 Peptides and Histone H3 , 2016, Angewandte Chemie.

[40]  Robert Preissner,et al.  Chemical Proteomics Reveals Ferrochelatase as a Common Off-target of Kinase Inhibitors. , 2016, ACS chemical biology.

[41]  L. Leclercq,et al.  Absorption, Metabolism, and Excretion of Oral 14C Radiolabeled Ibrutinib: An Open-Label, Phase I, Single-Dose Study in Healthy Men , 2015, Drug Metabolism and Disposition.

[42]  G. Drewes,et al.  Tracking cancer drugs in living cells by thermal profiling of the proteome , 2014, Science.

[43]  Chunaram Choudhary,et al.  The growing landscape of lysine acetylation links metabolism and cell signalling , 2014, Nature Reviews Molecular Cell Biology.

[44]  S. Knapp,et al.  Discovery and Optimization of Small-Molecule Ligands for the CBP/p300 Bromodomains , 2014, Journal of the American Chemical Society.

[45]  Junwei Shi,et al.  The mechanisms behind the therapeutic activity of BET bromodomain inhibition. , 2014, Molecular cell.

[46]  M. Redinbo,et al.  Bacterial β-glucuronidase inhibition protects mice against enteropathy induced by indomethacin, ketoprofen or diclofenac: mode of action and pharmacokinetics , 2014, Xenobiotica; the fate of foreign compounds in biological systems.

[47]  G. Ni,et al.  A phase I, open-label, mass balance study of [14C] dacomitinib (PF-00299804) in healthy male volunteers , 2013, Cancer Chemotherapy and Pharmacology.

[48]  D. Lewis,et al.  Modelling Species Selectivity in Rat and Human Cytochrome P450 2D Enzymes , 2013, PloS one.

[49]  R. Shah,et al.  Hepatotoxicity of Tyrosine Kinase Inhibitors: Clinical and Regulatory Perspectives , 2013, Drug Safety.

[50]  S. Knapp,et al.  Optimization of 3,5-Dimethylisoxazole Derivatives as Potent Bromodomain Ligands , 2013, Journal of medicinal chemistry.

[51]  J. Ambroso,et al.  Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds. , 2012, Chemical research in toxicology.

[52]  Stefan Knapp,et al.  The bromodomain interaction module , 2012, FEBS letters.

[53]  M. Redinbo,et al.  Pharmacologic Targeting of Bacterial β-Glucuronidase Alleviates Nonsteroidal Anti-Inflammatory Drug-Induced Enteropathy in Mice , 2012, Journal of Pharmacology and Experimental Therapeutics.

[54]  Hao Sun,et al.  Mechanism-based inactivation (MBI) of cytochrome P450 enzymes: structure-activity relationships and discovery strategies to mitigate drug-drug interaction risks. , 2012, Journal of medicinal chemistry.

[55]  John E. Scott,et al.  A High Throughput Assay for Discovery of Bacterial β-Glucuronidase Inhibitors , 2011, Current chemical genomics.

[56]  Wei Tang,et al.  Antitumor activity of extracts and compounds from the skin of the toad Bufo bufo gargarizans Cantor. , 2011, International immunopharmacology.

[57]  U. Boelsterli,et al.  NSAID acyl glucuronides and enteropathy. , 2011, Current drug metabolism.

[58]  U. Boelsterli.  Editorial [Hot Topic:Acyl Glucuronides: Mechanistic Role in Drug Toxicity? (Guest Editor: Urs A. Boelsterli)] , 2011 .

[59]  Zeruesenay Desta,et al.  In vitro and in vivo oxidative metabolism and glucuronidation of anastrozole. , 2010, British journal of clinical pharmacology.

[60]  Osamu Okazaki,et al.  Predictability of Idiosyncratic Drug Toxicity Risk for Carboxylic Acid-Containing Drugs Based on the Chemical Stability of Acyl Glucuronide , 2010, Drug Metabolism and Disposition.

[61]  Dominic P. Williams,et al.  Acyl glucuronides: the good, the bad and the ugly. , 2010, Biopharmaceutics & drug disposition.

[62]  M. Mann,et al.  Lysine Acetylation Targets Protein Complexes and Co-Regulates Major Cellular Functions , 2009, Science.

[63]  F. Guengerich,et al.  Human liver mitochondrial cytochrome P450 2D6 – individual variations and implications in drug metabolism , 2009, The FEBS journal.

[64]  Deepak Dalvie,et al.  Assessment of three human in vitro systems in the generation of major human excretory and circulating metabolites. , 2009, Chemical research in toxicology.

[65]  William M. Lee,et al.  Etiologies of acute liver failure. , 2008, Seminars in liver disease.

[66]  A. Kalgutkar,et al.  Genotoxicity of 2-(3-Chlorobenzyloxy)-6-(piperazinyl)pyrazine, a Novel 5-Hydroxytryptamine2c Receptor Agonist for the Treatment of Obesity: Role of Metabolic Activation , 2007, Drug Metabolism And Disposition.

[67]  F. Lombardo,et al.  BIOACTIVATION OF THE NONTRICYCLIC ANTIDEPRESSANT NEFAZODONE TO A REACTIVE QUINONE-IMINE SPECIES IN HUMAN LIVER MICROSOMES AND RECOMBINANT CYTOCHROME P450 3A4 , 2005, Drug Metabolism and Disposition.

[68]  F. Oesch,et al.  Metabolism of propafenone and verapamil by cryopreserved human, rat, mouse and dog hepatocytes: comparison with metabolism in vivo , 2004, Naunyn-Schmiedeberg's Archives of Pharmacology.

[69]  U. Boelsterli.  Xenobiotic acyl glucuronides and acyl CoA thioesters as protein-reactive metabolites with the potential to cause idiosyncratic drug reactions. , 2002, Current drug metabolism.

[70]  F. Guengerich,et al.  Common and uncommon cytochrome P450 reactions related to metabolism and chemical toxicity. , 2001, Chemical research in toxicology.

[71]  M. Gibaldi.  Adverse Drug Effect—Reactive Metabolites and Idiosyncratic Drug Reactions: Part I , 1992, The Annals of pharmacotherapy.

[72]  N. Vermeulen,et al.  A refined substrate model for human cytochrome P450 2D6. , 1997, Chemical research in toxicology.